



**CANCER CARE
FOUNDATION**

M O C CANCER CARE FOUNDATION

Annual Report 2024-25

**ADVANCING EARLY DETECTION AND TIMELY CANCER CARE
ACCESS ACROSS COMMUNITIES**



TABLE OF CONTENTS

A. Company Overview

Director's Address

About MOC

Our Team

Activities & Impact Report

Fundraising & Resource Mobilization

Future Plans

B. Statutory and Financial Reports

Board of Directors' Report

Auditor's Report

Financial Statements

Acknowledgement

• **REPORTING PERIOD**

The Reporting Period is 1st April 2022 to 31st March 2023

• **ASSURANCE & DATA QUALITY**

Financial statements are audited by independent statutory auditors. Data compilation and review controls are applied to enhance accuracy and reliability.



DIRECTOR'S ADDRESS

DEAR STAKEHOLDERS

It is with a deep sense of purpose and optimism that I present our Annual Report for 2024 -25; a year marked by meaningful expansion, strengthened capabilities, and a growing impact across communities.

I extend my heartfelt gratitude to our donors, partners, medical professionals, volunteers, and community health workers. Your continued trust and generosity have enabled us to translate intent into action and reach individuals who would otherwise remain outside the fold of timely cancer care.

Over the past year, we have remained steadfast in our mission to reduce the burden of cervical, oral, and breast cancers through early detection, awareness, and patient-centered support. Every initiative we undertake is guided by clinical expertise, grounded in evidence, and driven by a commitment to equitable access.

A transformative milestone in Mar 2024 has been the acquisition of our own outreach van -made possible through the unwavering support of our donors. This has significantly enhanced our ability to deliver services on the ground, enabling not only increased screening for early detection but also improved continuity through follow-up care and treatment navigation during 2024-25. Supported by a dedicated and tireless field team, this initiative allowed us to conduct 146 screening camps across Maharashtra, reaching diverse and often underserved populations with essential, potentially life-saving services.

What began as a largely urban effort has now evolved into a broader, state-wide movement. We are increasingly present in communities where awareness is limited and access to healthcare remains a challenge-bringing screening, education, and timely referrals directly to those who need them most.

Our approach continues to integrate medical expertise with community engagement, ensuring that prevention, early diagnosis, and care pathways are seamlessly connected. At the same time, our ongoing engagement with research and data-driven practices ensures that our work remains relevant, effective, and aligned with emerging public health needs.

The progress we have made this year is a direct reflection of your support. As we look ahead, we aim to further scale our outreach, deepen our impact, and move closer to a future where no life is lost to cancers that can be prevented or treated when detected early.

We remain deeply grateful for your partnership and look forward to continuing this journey together.

Warm regards,
Dr. Vashista Maniar
MOC Cancer Care Foundation

ABOUT MOC CANCER CARE FOUNDATION



ORGANISATION DETAILS

Type: Section 8 (Not-for-Profit)

Established: 2018

CIN:
U85300MH2018NPL318472

Registered Office:

1st & 2nd Floor, Shree Saraswati Apartments, CHSL, Opp. Bhagwati Hospital, S.V. Road, Borivali West, Mumbai – 400092

Communication Address:

3rd, 4th & 5th Floor, Time Square Building, Scindia Society, Bima Nagar, Andheri East, Mumbai – 400069

Website:

www.mocfoundation.com

ABOUT THE ORGANISATION

Founded in 2018 under Section 8 of the Companies Act, MOCF is a not-for-profit organization working to enhance cancer outcomes through early identification and timely care pathways. Its programs are implemented with clinical support from M|O|C Cancer Care & Research Centre, ensuring an integrated approach that bridges community outreach with medical expertise.

Vision: To create a future where early cancer detection is accessible to all, leading to improved survival and healthier communities.

FOCUS ON EARLY DETECTION

- **Breast Cancer**
- **Cervical Cancer**
- **Oral Cancer**

By addressing gaps in awareness, screening, and access, MOCF aims to reduce late-stage diagnoses and improve survival outcomes.

REGULATORY APPROVALS

| Registration | Purpose | Validity |
|------------------|---|------------------------------|
| 12A Registration | Income Tax Exemption Status (Date: 31.08.2021) | A.Y. 2022-23 to A.Y. 2026-27 |
| 80G Certificate | Donor Tax Deduction Benefit (Date- 20.11.21) | A.Y. 2022-23 to A.Y. 2026-27 |
| CSR Registration | MCA-issued; enables CSR funding under Sec. 135 (Date: 05.04.2021) | Subject to Compliance |

STRATEGIC FOCUS & IMPACT APPROACH

- **AWARENESS & SCREENING PARTICIPATION**

Targeted IEC (Information, Education, Communication) campaigns and mobilisation to improve screening uptake.

- **EARLY IDENTIFICATION & NAVIGATION**

Community-based screening initiatives and structured patient navigation for timely diagnosis and treatment.

- **LAST-MILE MOBILISATION**

Outreach to underserved and high-risk populations, strengthening grassroots-level engagement.

- **SCALE & SUSTAINABILITY**

Expansion of program footprint across geographies and building sustainable, replicable intervention models.

- **CONVERGENCE & ACCESS**

Integration with public health systems and partner organisations, improving access to diagnostic and treatment services.

IMPACT APPROACH

EARLY DETECTION

Reducing diagnostic delays through proactive community screening.

SYSTEM STRENGTHENING

Leveraging partnerships for scale and sustainability.

EQUITABLE ACCESS

Reaching vulnerable and underserved populations.

CONTINUUM OF CARE

Ensuring referral completion from screening to treatment.

CSR PARTNERSHIP OPPORTUNITY: MOCF offers a high-impact platform for CSR engagement through scalable community screening programs, measurable health outcomes, strong on-ground implementation and clinical linkage, and alignment with national health priorities.

OUR BOARD OF DIRECTORS

DR. ASHISH ANAND JOSHI

M.D (Internal Medicine)
D.M (Medical Oncology)



Speciality- Medical and Pediatric Hemato-Oncologist.

One of the important pillar of BOD is Dr. Ashish Joshi. A distinguished Medical and Pediatric Hemato-Oncologist, he trained at Byramjee Jeebhoy Medical College and Sassoon Hospital, Pune, and the Gujarat Cancer Research Institute, Ahmedabad, where he was awarded a gold medal for academic excellence.

With deep expertise across cancers and hematological disorders, including advanced therapies such as bone marrow and stem cell transplantation, Dr. Joshi combines clinical excellence with a strong ethos of empathy and service. Under his guidance, we continue to advance our mission of making quality cancer care accessible to all, delivered with dignity, compassion, and hope.

DR. KSHITIJ CHANDRAKANT JOSHI

M.D (Internal Medicine)
D.M (Medical Oncology)
DNB (Diplomate of National Board)
ECMO (European Certification in Medical Oncology)



Speciality - Medical and Pediatric Hemato-Oncologist.

We are pleased to highlight the contributions of Dr. Kshitij Joshi, a trustee of our NGO and an accomplished oncologist with over a decade of experience. Trained at the Gujarat Cancer Research Institute, Ahmedabad, he holds MD, DM, DNB, and ECMO qualifications.

Dr. Joshi brings extensive expertise in managing solid tumors and hematological malignancies, with a special interest in immunology. He is actively engaged in academic work, publications, and teaching. His clinical insight, vision, and compassionate approach play a vital role in advancing our mission of cancer care and awareness.

OUR BOARD OF DIRECTORS

DR. PREETAM BABAN KALASKAR

M.D (Internal Medicine)
D.M (Medical Oncology)

Speciality - Medical and Pediatric Hemato-Oncologist.



We are proud to highlight the contributions of Dr. Preetam Baban Kalaskar, an accomplished Medical and Pediatric Hemato-Oncologist and Gold Medalist, with advanced training in Internal Medicine and Medical Oncology from the Gujarat Cancer Research Institute, Ahmedabad.

Dr. Kalaskar brings a strong blend of clinical excellence and academic experience, having taught both undergraduate and postgraduate students and contributed to reputed national and international journals. His expertise spans a wide spectrum of solid tumors and hematological malignancies, along with active involvement in bone marrow transplant programs.

Guided by a commitment to accessible, high-quality cancer care, Dr. Kalaskar exemplifies our mission of combining advanced medical expertise with compassionate, patient-centered treatment.

DR. VASHISTA PANKAJ MANIAR

(M.D (Internal Medicine)
D.M (Medical Oncology)
ECMO (European Society Certification in Medical Oncology)

Speciality - Medical and Pediatric Hemato-Oncologist.



Dr. Vashista Maniar is a distinguished Medical and Paediatric Oncologist and Hemato-Oncologist with strong academic credentials and extensive clinical expertise. He earned his M.D. from Lokmanya Tilak Medical College, Mumbai, and his D.M. from Gujarat Cancer Research Institute, Ahmedabad, receiving a gold medal for academic excellence. He specializes in managing solid tumours and haematological malignancies and has made significant contributions to bone marrow and stem cell transplant programs. An active educator, he is dedicated to training medical students and residents. His expertise and commitment have greatly enhanced clinical care, academic growth, and the overall advancement of cancer services within his organization.

OUR MENTORS



Mr. Saurabh Desai

Associate Director

Mr. Saurabh Desai, Associate Director, is instrumental in translating the organization's vision into action. With a background outside the medical field, Mr. Desai contributes diverse expertise and a strong sense of purpose, working closely with teams to enhance program delivery, build partnerships, and further the foundation's mission in cancer care.



Mr. Nitin Sheth

Mentor and Advisor of MOCF

Since joining the organization in 2021, Mr. Nitin Sheth has served as a Mentor and Advisor, bringing a strong commitment to the cause and a perspective rooted outside the medical domain. Aligned with the foundation's mission, Mr. Nitin offers strategic guidance and supports the development of initiatives that strengthen outreach, sustainability, and community impact.

ACTIVITIES & IMPACT

The Mobile Van: A Lifeline for Early Detection



The Cancer Van initiative continues to serve as a vital outreach program aimed at improving early detection, awareness, and access to basic cancer screening services, especially in underserved and remote communities.

146

SCREENING CAMPS CONDUCTED
ACROSS MAHARASHTRA IN
2024-25

PURPOSE

ENHANCE EARLY DETECTION
THROUGH ACCESSIBLE AND
AFFORDABLE SCREENING SERVICES

REACH

UNDERSERVED AND REMOTE
COMMUNITIES ACROSS THE STATE

PROGRAM OBJECTIVES

EARLY DETECTION

Promote regular health check-ups and cancer screenings among at-risk populations.

FACILITATE REFERRALS

Connect individuals requiring further diagnosis and treatment to appropriate healthcare facilities

EDUCATE COMMUNITIES

Raise awareness about cancer risk factors, symptoms, and preventive measures.

REDUCE CANCER BURDEN

Reduce overall cancer morbidity and mortality through early intervention and follow-up care.

The Mobile Van: A Lifeline for Early Detection

Our Impact at a Glance



- Community Mobilization & Awareness**
 Before each camp, the initiative partners with local leaders, NGOs, and healthcare workers to spread awareness about early cancer detection through community outreach, local media, and educational activities, ensuring high attendance and active participation at the camps.



- On-Site Screening & Early Detection**
 The mobile van, equipped with advanced screening tools, provides accessible and high-quality cancer screenings in underserved communities, enabling early detection and timely medical intervention..



- Immediate Diagnosis & Counseling**
 Patients identified with potential risks receive immediate preliminary findings, compassionate counseling, and clear guidance on the next steps for timely diagnosis and treatment.



- Seamless Referral & Navigation Support**
 Patients needing further care are referred to specialized hospitals, while dedicated support teams assist with appointments, financial guidance, and treatment navigation for a smooth care journey.

MAMMOGRAPHY AND PAP SMEAR TEST CAMPS CONDUCTED DURING 2024-25

Bridging Healthcare Gaps

The 2024 Screening Initiative focused on high-risk cancer detection in tier-2 and tier-3 cities of Maharashtra. Our primary goal was to provide accessible, high-quality diagnostics to women who lack regular medical check-ups.

Awareness: Educating beneficiaries on self-examination and preventive care

Early Detection: Identifying breast and cervical anomalies at Stage 0/1.

Linkage: Connecting positive cases to concern hospitals.



Cumulative Impact

4045

TOTAL BENEFICIARIES
Across 10 Strategic Locations

3014

MAMMOGRAMS
Advanced Breast Screening


1031

PAP SMEARS
Cervical Health Screenings

Quarterly Performance Summary

| Quarter (FY 24-25) | Camps Conducted | Mammography | Pap Smears |
|--------------------|-----------------|-------------|------------|
| Q1 (Apr - Jun) | 13 | 282 | 119 |
| Q2 (Jul - Sep) | 18 | 423 | 31 |
| Q3 (Oct - Dec) | 22 | 438 | 86 |
| Q4 (Jan - Mar) | 93 | 1,871 | 795 |

Screening Distribution by Location



Geographic Footprint



📍 Mumbai & MMR Hub
 Intensive coverage across Thane, Panvel, Vashi, and Kalyan. These areas represented the highest concentration of camps in the suburban corridor.

📍 Pune & Western Region
 A major diagnostic base centered at Dwarka Hospital (Kothrud), extending outreach to Bavdhan, Baner, and Shivaji Nagar clusters.

Monthly Camp Distribution Trends



The data reveals a consistent upward trajectory in camp frequency, peaking in Q4 as outreach efforts intensified across the state.



Conclusion

The MOC Cancer Care Foundation Cancer Van initiative conducted a cancer awareness and screening program focused on early diagnosis and preventive healthcare, particularly for breast and cervical cancer. By delivering essential services directly to communities, the initiative continues to improve awareness and access to timely cancer care in underserved areas.

FUNDRAISING & RESOURCE MOBILIZATION

FY 2024-25: Year of Breakthrough

175%

Year-on-Year Growth

Increase in Resource Mobilization

Donation Inflow

+175%

Beneficiary Reach

+85%

Operational Surplus

Turnaround

The "Moving Billboard" Strategy




Mobile Mammography Unit

Launched as a specialized CSR asset, this van has catalyzed community engagement and donor trust across Pune and Maharashtra.

Key Achievements:

- 4,000+ Women screened in Year 1.
- High visibility for CSR partners.
- Early detection of 15+ potential cases.

Our Funding Mix



Four Pillars of Growth



Smart Screening

AI-driven diagnostics & high-risk cohort tracking.



Health Champions

Developing local community leadership models,



Holistic Care

Integration of nutrition & psycho-social support.



Sustainability

Corpus building & multi-year CSR commitments.

FUNDRAISING & RESOURCE MOBILIZATION

Pillars 1 & 2: Detection & Leadership



Smart Screening

Implementing risk-based mobile camps. Moving from random screening to "Risk Score" based interventions to improve Hit Rate.



Health Champions

Training 500+ local women as 'MOC Health Champions' to drive door-to-door awareness and screening referrals.

Pillar 3: Holistic Patient Support

Continuum of Care

We are evolving from providing financial aid to offering a complete recovery ecosystem.

- **Nutritional Support:** Onco-specific diet kits
- **Mental Wellness:** Counseling for patients & families.
- **Navigational Aid:** Helping patients access Govt schemes..




Pillar 4: Resource Allocation 2024-25

Capacity Building & Ops (10%)

Community Leadership Programs (20%)

Financial Assistance & Support (30%)



100% Utilisation

Screening & Early Detection (40%)

- Screening & Early Detection (40%)
- Financial Assistance & Support (30%)
- Community Leadership Programs (20%)
- Capacity Building & Ops (10%)

FUTURE ROADMAP FOR MOCF (FY 2025–26)

Empowerment Through Innovation & Scale

Moving from service delivery to a long-term sustainability model focused on intelligence, community leadership, and holistic care.



Data-Driven Targeting

Shift from general camps to risk-based screening using lifestyle and demographic analytics.



Specialized Camps

Focused workplace drives (factories/offices), women-only camps, and oral cancer screenings.



End-to-End Tracking

Integrated digital journey from initial screening to diagnosis and final treatment.

Community Leadership Networks

The Health Champion Program

Developing a robust grassroots awareness network through training and certification.

- Train local women, youth, and survivors as leaders.
- Provide professional certification and incentives.
- Drive hyper-local awareness in underserved clusters.



Holistic Rehabilitation Programs



Physical Wellness

Yoga and light exercise sessions specifically tailored for physical recovery.



Mental Resilience

Family counseling and peer support groups to manage emotional impact.



Wellness Retreats

Annual wellness camps and retreats for patients and their caregivers.

Holistic Rehabilitation Programs

| Initiative Type | Strategic Focus | Target Outcome |
|--------------------------|--|---------------------------------|
| Social Enterprise | Awareness merchandise (apparel, bands) | Self-sustaining revenue streams |
| Micro-Donations | Establishing digital giving platforms | High-volume retail philanthropy |
| CSR Partnerships | Multi-year strategic commitments | Long-term operational stability |

FUTURE ROADMAP FOR MOCF (FY 2025–26)

Patient Support Ecosystem

Continuum of Care

Providing a safety net from first detection to post-treatment recovery.


Infrastructure Goals:

- Funding for Early Diagnosis & Treatment.
- Digital helpline for immediate guidance.
- Low-cost accommodation near hospitals.
- Post-treatment nutrition & medication.



Monitoring & Impact Measurement

Deploying advanced analytics dashboards to track mission-critical KPIs:



Population Coverage

Conversion Rates

Quality-of-Life Index

Strategic Expected Outcomes

- **Efficiency:** High-risk identification optimization via data.
- **Ownership:** Strong community-led prevention models.
- **Sustainability:** Diversified and scalable funding channels.
- **Dignity:** Measurable improvement in patient quality of life.



Goal: 2026 Milestone
 Transitioning from a service-delivery charity to a systemic healthcare movement in India.

Focus: Smart Detection

Moving beyond traditional camps. We are integrating medical expertise with mobile technology to ensure no patient is left behind.

- Tobacco-user focused oral drives.
- Workplace on-site screenings.
- Immediate digital referral links.

Towards a Cancer-Free Tomorrow

STATUTORY & FINANCIAL COMPLIANCE

BOARD OF DIRECTORS' REPORT

To,
The Members,
MOC Cancer Care Foundation

Our directors have the pleasure of presenting the 07th Annual Report on the business and operations of the Company along with the audited financial statements of MOC CANCER CARE FOUNDATION ("Company") for the financial year ended on 31st March, 2025.

| Particulars | Year ended 31st March, 2025 | Year ended 31st March, 2024 |
|---|-----------------------------|-----------------------------|
| Income from Operations | 81.8 | 29.58 |
| Other Income | 0 | 0.15 |
| Finance Income | - | - |
| Total Income | 81.38 | 29.73 |
| Less: Total expenses | 54.8 | 46.58 |
| Surplus/Deficit for the period | 26.58 | -16.85 |
| Less: Current Tax | 0.45 | - |
| Earlier Year Tax | 0.44 | - |
| Surplus/ Deficit Carried Forward | 25.7 | -16.85 |

- PRESENTATION OF FINANCIAL STATEMENTS:** The financial results are based on the audited financial statements of the Company for the financial year ended 31st March, 2025, prepared in accordance with the applicable accounting standards and the requirements of the Companies Act, 2013. The financial statements have been drawn up on a prudent basis, so as to give a true and fair view of the state of affairs of the Company, including its financial performance and cash flows for the year ended 31st March, 2025. During the year under review the total turnover of the company was Rs. 81.38 Lakhs. The Company has reported surplus of Rs. 25.70 Lakhs as compared to the deficit of Rs. 16.85 Lakhs in the previous financial year.
- OPERATIONS:** During the year under review the Company has a social object to provide medical treatment and assistance to poor and deserving patients including providing medicines and other medical support to patients for free or affordable charges and to set up or tie up with Health Care Centres / Institutes where services of experts are provided free or at reasonable charges and to organize free medical camps for cancer and other diseases patients and to open or tie up with Centres/Institutes for clinical trials, research on cancer and for another deadly disease to initiate or participate in awareness drive for cancer and other diseases and to provide Medical Education, Medical Services, Media Research and impart training in the areas of medicines and clinical research and construct and manage the Medical College and Research Institution.

- **STATE OF COMPANYS' AFFAIRS AND FUTURE OUTLOOK:** MOC Cancer Care Foundation, incorporated on 18th December 2018 as a Section 8 Company, is registered at 1st & 2nd Floor, Shree Saraswati Apartments, CHSL, Opposite Bhagwati Hospital, S.V. Road, Borivali West, Mumbai – 400092, Maharashtra, India. The Foundation is dedicated to a social mission focused on providing free or affordable medical treatment, organizing awareness drives, supporting clinical research, and establishing healthcare centers, medical education, and training institutions.
 - **Future Outlook:** MOC Cancer Care Foundation is well-positioned to make a significant impact in the healthcare sector, addressing the growing need for accessible cancer treatment, research, and education. By expanding its network of healthcare centers, organizing awareness campaigns, and fostering partnerships with both government and private sectors, the Foundation can serve more underserved communities. Its focus on clinical research, innovative treatment options, and training healthcare professionals will help improve cancer care while developing a skilled workforce. With diversified funding, strategic collaborations, and the use of technology like telemedicine, MOC Cancer Care Foundation can contribute to advancing cancer prevention, treatment, and research across India.
- **DIVIDEND:** As per the provisions of the Companies Act, 2013, a Section 8 Company is prohibited from declaring or distributing any dividend to its members. Accordingly, the Company has not declared any dividend for the financial year under review.
- **TRANSFER TO RESERVES:** During the year under review, the company has earned Surplus of Rs. 25.70 Lakhs and the same has been carried forward to Balance Sheet under the head other equity of Financial Statement 2024-25.
- **SHARE CAPITAL:**
 1. Authorized Share Capital: As on 31st March, 2025, the Authorized Share Capital of the Company is Rs. 1,00,000/- (Rupees One Lakh only), divided into Rs. 10,000/- (Ten Thousand) Equity shares of Rs. 10 (Rupees Ten only) each. No alteration to authorized share capital OR Paid-up share capital has been made during the year under review.

| Particulars | Issued Capital (INR) | Subscribed Capital (INR) | Paid-up Capital (INR) |
|---------------|----------------------|--------------------------|-----------------------|
| Equity Shares | 10000 | 10000 | 10000 |
| Face Value | 10 | 10 | 10 |
| Total | 100000 | 100000 | 100000 |

2. Issue of Equity Shares with differential rights, Sweat Equity, ESOP:

During the year under review:

- The Company has not granted or issued any Employee Stock Option Scheme (ESOP) to its employees.
 - The Company has not issued any sweat equity shares, and accordingly, the provisions of Rule 8(13) of the Companies (Share Capital and Debentures) Rules, 2014 are not applicable.
 - The Company has not issued any equity shares with differential rights as to dividend, voting, or otherwise.
- **CHANGE IN THE NATURE OF BUSINESS, IF ANY:** During the year under review, there has been no change in the nature of the business activity of the company.

- **SHIFTING OF REGISTERED OFFICE:** During the year under review the company shifted its Registered Office.

| Old Registered Office Address | New Registered Office Address | Effective Date |
|---|--|----------------|
| 1st Floor, Khodiyar Apartment, Daulat Nagar, Rd No. 6, Borivali East, Mumbai 400066 | 1st & 2nd Floor, Shree Saraswati Apartments CHSL, Opposite Bhagwati Hospital, S.V. Road, Borivali West, Mumbai- 400092 | 7th May 2024 |

- **DIRECTORS AND KEY MANAGERIAL PERSONNEL:** There has been no change in the composition of the Board of Directors of the Company during the year under review. The existing Directors continued to hold office as on the date of this Report.

Thus, at the end of the financial year 2024-25, the composition of the Board of Directors and KMP of the Company is as under:

| Sr. No. | Name of Director(s) | DIN | Category |
|---------|---------------------------|---------|----------|
| 1 | Ashish Anand Joshi | 7958653 | Director |
| 2 | Vashista Pankaj Maniar | 7958648 | Director |
| 3 | Kshitij Chandrakant Joshi | 7958657 | Director |
| 4 | Preetam Baban Kalaskar | 7958660 | Director |

- On the basis of the written representations received from the directors, none of the above directors are disqualified under sections 164(1) & 164(2) of the Companies Act, 2013. The provisions of section 197(14) of the Companies Act, 2013, in relation to disclosure of remuneration or commission received by a Managing or Whole-Time Director from the company's holding or subsidiary company are not applicable to the Company.
- **Independent Director:** The Company was not required to appoint Independent Directors under section 149(4) read with Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 and hence no declaration has been obtained under section 149(7) of the Companies Act, 2013. Further the requirement of familiarization program of Independent Directors is also not applicable.
- **MEETINGS OF THE BOARD AND COMMITTEE:**
 - During the financial year under review, the Board of Directors met on the dates stated below.

| Sr. No. | Name of the director | Date of Board Meeting and their Attendance | | | | Meetings eligible to attend and attended |
|---------|----------------------|--|------------|------------|------------|--|
| | | 07.05.2024 | 14.09.2024 | 18.09.2024 | 04.01.2025 | |
| 1 | Ashish Joshi | Yes | Yes | Yes | Yes | 4/4/2026 |
| 2 | Vashista Maniar | Yes | Yes | Yes | Yes | 4/4/2026 |
| 3 | Kshitij Joshi | Yes | Yes | Yes | Yes | 4/4/2026 |
| 4 | Preetam Kalaskar | Yes | Yes | Yes | Yes | 4/4/2026 |

The meetings were convened in compliance with the provisions of the Companies Act, 2013 and the Secretarial Standards issued by the Institute of Company Secretaries of India. The prescribed quorum was present at each meeting, and agenda papers along with relevant documents were circulated in advance to facilitate informed decision-making by the Board.

The provisions of the Companies Act, 2013 and the rules made thereunder relating to the constitution of committees of the Board are not applicable to the Company. Accordingly, no committees have been constituted and, consequently, no committee meetings were held during the financial year under review.

- **DIRECTORS' RESPONSIBILITY STATEMENT:**

- Pursuant to the provisions of Section 134(5) of the Act, your Board of Directors confirm, to the best of their knowledge and ability, that:

1. In the preparation of the annual accounts for the financial year ended 31st March, 2025, the applicable accounting standards read with the requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
2. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as of 31st March, 2025, and of the profit and loss of the Company for the year ended on that date;
3. The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
4. The Directors have prepared the annual accounts on a "going concern" basis;
5. The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and such systems were adequate and operating effectively.

- **STATUTORY AUDITOR:** Pursuant to the provisions of Section 139, 141 of the Companies Act, 2013 and rules made thereunder (hereinafter referred to as "The Act") M/s. P. L. Raval & Co. (FRN: 108747W), Chartered Accountants, Mumbai were reappointed as the Statutory Auditors of the Company at the Sixth Annual General Meeting to hold office for a term of 5 (Five) years and they continue to be the statutory auditors of the company.

- **AUDITORS REPORT:** The Auditors' Report to the members on the Accounts of the Company for the financial year ended 31st March, 2025, does not contain any qualification or any adverse remarks.

- **AUDITOR'S QUALIFICATION:** There are no qualifications in the reports of the Statutory Auditors and Secretarial Auditor. There was no instance of fraud during the year under review, which is required to be reported by Statutory Auditors in their reports as mentioned under sub-section (12) of Section 143 of the Act.

- **WEB ADDRESS AND ANNUAL RETURN:** Pursuant to amended provision of Section 134(3)(a) read with section 92(3) of the Companies Act 2013, every company is required to place a copy of the annual return on its' website, (if any), and the web-link of such annual return shall be disclosed in the Board's report. Since the company has its own website, any person desirous of viewing contents of annual return may visit the following link <https://www.mocfoundation.com/> to view the contents. Further, a physical copy of the Annual Return is also available for inspection at the Registered Office of the Company on all working days during business hours.

- **CONTRACT AND ARRANGEMENT WITH RELATED PARTIES:** During the financial year under review, the related party transactions that were entered were in the ordinary course of the business of the Company and were on an arm's length basis. The disclosure of particulars of contracts/ arrangement entered into by the Company with the related parties referred to in Section 188 of the Companies Act, 2013 are attached to this report in Form AOC-2 as Annexure I. Disclosures on related party transactions carried out during the financial year 2024-25 are also provided in Note No. 3.15 in Notes to the financial statements.
- **PARTICULARS OF INVESTMENTS, LOANS, GUARANTEE AND SECURITIES:** During the year under review, the Company has not given any loans or guarantees, provided any security, or made any investments falling within the purview of Section 186 of the Companies Act, 2013. Accordingly, the disclosure requirements under the said section are not applicable for the year under review.
- **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:** Section 134(3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 is forming part of the board 's report for the financial year 2024-2025.

The details of the conservation of energy, technology absorption, foreign exchange earnings, and outgo are as follows:

| A | CONSERVATION OF ENERGY | |
|------|--|---|
| i) | Steps taken or impact on conservation of energy | The Company is not engaged in any manufacturing activity. However, it continues to promote energy conservation at the workplace by sensitising employees on the importance of avoiding energy wastage and adopting efficient practices. |
| ii) | Steps taken by the Company for utilizing alternate sources of energy | No specific measures have been adopted for the use of alternate sources of energy. However, the Company continues to make every effort to conserve energy in its operations. |
| iii) | Capital investment on energy conservation equipment | Nil |

| B TECHNOLOGY ABSORPTION | | |
|---------------------------------------|---|------|
| i) | Efforts made towards technology absorption | None |
| ii) | Benefits derived from technology absorption | None |
| iii) | Details of Imported technology (last three years) | N.A. |
| | - Details of technology imported | |
| | - Year of import | |
| | - Whether technology being fully absorbed | |
| | - If not fully absorbed, areas where absorption has not taken place and reasons thereof | |
| iv) | Expenditure incurred on Research and development | Nil |
| C FOREIGN EXCHANGE EARNINGS AND OUTGO | | |
| i) | Foreign Exchange inflow | - |
| ii) | Foreign Exchange outflow | - |

- **RISK MANAGEMENT POLICY:** The Board of Directors of the Company has designed Risk Management Policy and Guidelines to avoid events, situations or circumstances which may lead to negative consequences on the Company's business and define a structured approach to manage uncertainty and to make use of these in their decision-making pertaining to all business divisions and corporate functions. Key business risks and their mitigation are considered in the annual/strategic business plans and in periodic management reviews.
- **PARTICULARS OF EMPLOYEES:** The provisions of Section 197(12) of the Act, read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are not applicable to the Company. Hence, a statement showing the names and other particulars of the top ten employees in terms of remuneration drawn including employees drawing remuneration in excess of the limits set out in the said rules is not enclosed herewith to this Report.

- **DISCLOSURE AND INTERNAL COMPLAINTS COMMITTEE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:** The Company maintains a zero-tolerance policy towards sexual harassment and has in place a mechanism for prevention and redressal of complaints at the workplace. An Internal Complaints Committee has been constituted to handle any complaints received. During the financial year 2024-25, the Company did not receive any complaints of sexual harassment. The Company continues to conduct awareness programs to ensure a safe and respectful work environment for all employees.

| Sr. No. | Particulars | Details |
|---------|---|---------|
| (i) | Number of Sexual Harassment Complaints received | Nil |
| (ii) | Number of Sexual Harassment Complaints disposed off | Nil |
| (iii) | Number of Sexual Harassment Complaints pending beyond 90 days | Nil |

- **MATERNITY BENEFIT:** The Company hereby confirms that it has fully complied with all provisions of the Maternity Benefit Act, 1961. During the year under review, the Company ensured that all eligible women employees received the statutory maternity benefits, including paid maternity leave, medical benefits, and other entitlements as prescribed under the Act. The Company remains committed to supporting the well-being of its women employees and fostering a family-friendly work environment.
- **MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:** There have been no material changes and commitments, affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.
- **SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:** There have been no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and the Company's operations in future.
- **NUMBER OF EMPLOYEES AS ON THE CLOSURE OF THE FINANCIAL YEAR**

| GENDER | Nos |
|-------------|-----|
| Female | 3 |
| Male | 3 |
| Transgender | 0 |

- **INDUSTRIAL RELATIONS:** The industrial relations with staff and workers during the year under review continue to be cordial.
- **DEPOSITS:** During the year under review, the Company has not accepted any deposits falling within the meaning of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014. As required under Rule 16A of the Companies (Acceptance of Deposits) Rules, 2014,

the Company has neither borrowed any amount from its directors or relatives of directors during the financial year under review nor there is any outstanding amount as on 31st March 2025.

- **DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS:** The Company has in place adequate internal financial controls commensurate with the size, scale and complexity of its operations. During the financial year, such controls were tested and no reportable material weakness in the design or operation was observed.
- **INSOLVENCY AND BANKRUPTCY CODE 2016:** There were no such instances during the reporting period and preceding years.
- **ONE TIME SETTLEMENT WITH BANKS AND FINANCIAL INSTITUTIONS:** The Company has not entered into any One-time settlement with Banks or Financial Institutions.
- **CAUTIONARY STATEMENTS:** Certain statements in the “Director’s Report” describing the Company’s views about the industry, expectations/ predictions, objectives etc., may be forward looking within the meaning of applicable laws and regulations. Actual results may differ materially from those expressed in the Statement. Company’s operations may inter-alia affect with the supply and demand stipulations, input prices and their availability, changes in Government regulations, taxes, exchange fluctuations and other factors such as Industrial relations and economic developments etc. Investors should bear the above in mind.
- **DEPOSITORY SYSTEM:** The Ministry of Corporate Affairs (“MCA”) vide its notification dated October 27, 2023, amended the Companies (Prospectus and Allotment of Securities) Rules 2014, by inserting Rule 9B which required certain companies to facilitate dematerialization to its existing securities holders and has mandated that the stake of promoters, directors and key managerial personnel should be held in dematerialized form. In compliance with the said provisions, the company has obtained ISIN from the depository. The process of dematerialization of the company’s existing securities is currently in progress and necessary steps are being undertaken to ensure full compliance with the applicable regulatory requirements.
- **GREEN INITIATIVE:** The Ministry of Corporate Affairs (“MCA”) has undertaken a green initiative in Corporate Governance by allowing paperless compliances by the Companies and has permitted the service of Annual Reports and documents to the shareholders through electronic mode subject to certain conditions and the Company can send Annual Reports and other communications in electronic mode to the members who have registered their email addresses with the Company.
- **ACKNOWLEDGEMENT:** Your Directors acknowledge the valuable contribution of all its employees at all levels in the continuous growth of the Company. The Directors would also like to thank the Company’s, Investors, Banks, Government Authorities, Customers, Vendors, Employees and other Stakeholders for their continued co-operation and support in the Company’s growth and in its operations.

For and on behalf of the Board of MOC Cancer Care Foundation

Place: Mumbai
Date: 29/09/2025

SD/-
Vashista Maniar
Director
(DIN:07958648)
SD/-
Kshitij Joshi
Director
(DIN:07958657)

SD/-
Ashish Joshi
Director
(DIN: 07958653)
SD/-
Preetam Kalaskar
Director
(DIN:07958660)

Annexure-I

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto.

- **Details of contracts or arrangements or transactions not on an Arm's length basis:** Not Applicable. During the financial year under review, there were no contracts or arrangements or transactions entered by the Company with related parties not at Arm's Length Basis.

- **Details of material contracts or arrangement or transactions at arm's length basis:**

- Name(s) of the related party and nature of relationship

| Sr. No. | Name of the related party | Nature of Relationship |
|---------|---|--------------------------------------|
| 1 | Dr. Vashista Pankaj Maniar | Directors & Key Managerial Personnel |
| | Dr. Ashish Anand Joshi | |
| | Dr. Kshitij Chandrakant Joshi | |
| | Dr. Preetam Baban Kalaskar | |
| 2 | M/s. Cellcure Cancer Centre Private Limited | KMP having substantial interest |

- Nature of contracts/arrangements/transactions

| Sr. No. | Particulars | Nature of Transaction |
|---------|---|--|
| 1 | Dr. Vashista Pankaj Maniar | Donation Received |
| 2 | M/s. Cellcure Cancer Centre Private Limited | Medical Aid approved for treatment of patients |

- Duration of the contracts/arrangements/transactions: As per mutually agreed terms.
- Salient terms of the contracts or arrangements or transactions including the value, if any: As per mutually agreed terms.
- Date(s) of approval by the Board, if any: 07/05/2024
- Amount paid as advances, if any: Not applicable

For and on behalf of the Board of MOC Cancer Care Foundation

Place: Mumbai
Date: 29/09/2025

SD/-
Vashista Maniar
Director (DIN:07958648)
SD/-
Kshitij Joshi
Director (DIN:07958657)

SD/-
Ashish Joshi
Director (DIN: 07958653)
SD/-
Preetam Kalaskar
Director (DIN:07958660)

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF
MOC CANCER CARE FOUNDATION

- **Report on the Audit of the Financial Statements Opinion:** We have audited the accompanying financial statements of MOC Cancer Care Foundation ("the Company"), which comprise the Balance Sheet as at March 31, 2023, the Statement of Income and Expenditure account, the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (herein after referred to as "the financial statements"). In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, the surplus and its cash flows for the year ended on that date.
- **Basis for Opinion:** We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.
- **Information other than the Financial Statements and Auditors report thereon:** The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. The Director's Report is not made available to us at the date of this auditor's report and hence we have nothing to report in this regard.
- **Responsibilities of Management for the Financial Statements:** The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of The Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements: Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not guaranteed that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentation, or the override of the internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143 (3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the Audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonable be thought to bear on our independence, and where applicable, related safeguards.

- **Report on Other Legal and Regulatory Requirements:** Considering exception granted under Companies (Auditor's Report) Order, 2020, issued by the Central Government of India in terms of sub-section (I I) of the section 143 of the Companies Act, 2013, reporting under paragraph 3 and 4 of the order is not required.







- (A) As required by Section 143(3) of the Act, based on our audit we report that:
 - We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - The Balance Sheet, the Statement of Income and Expenditure Account including the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
 - In our opinion, the aforesaid financial statements comply with the Accounting standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - On the basis of the written representations received from the directors as on March 31, 2025, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
 - Considering the amendment made to section 143(3) of the Companies Act, 2013 vide Notification No. G.S.R. 583(E) dated 13th June 2017 read with General Circular No 08/2017 dated 25th July, 2017, reporting under clause (1) of section 143(3) is not applicable to the Company.
- (B) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - According to the information given to us, the Company does not have any pending litigations which would impact its financial position.
 - According to the information given to us, the company has not entered into any long-term contracts including derivative contracts.
 - There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
 - (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:
 - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or
 - provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
 - (b) The management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:
 - directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or
 - provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries; and
- Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub clause (iv) (a) and (iv) (b) contain any misstatement.
- According to information and explanation given to us, the Company has not declared any dividend in terms of provision of section 123 of Companies Act, 2013.

The provisions of Section 197 read with Schedule V to the Act are applicable only to public companies. Accordingly, reporting under Section 197(16) of the Act is not applicable to the Company.

For P. L. Raval & Co.
Chartered Accountants
FRN:108747W
SD/-
CA Piyush L. Raval

BALANCESHEET







AS ON 31 MAR 2025

| MOC CANCER CARE FOUNDATION | | | |
|--|----------|--|-----------------------|
| (A Company Licensed under Section 8 of the Companies Act, 2013) | | | |
| BALANCE SHEET AS AT 31ST MARCH 2025 | | | |
| (All amounts in INR Lakhs unless otherwise stated) | | | |
| Particulars | Note No. | As at 31/03/2025 ₹ | As at 31/03/2024 ₹ |
| I. EQUITY AND LIABILITIES | | | |
| (1) Shareholder's Funds | | | |
| (a) Share Capital | 3.01 | 1.00 | 1.00 |
| (b) Reserves and Surplus | 3.02 | 107.11 | 91.55 |
| (2) Non-Current Liabilities | | | |
| (a) Other Long-term borrowings | | - | - |
| (3) Current Liabilities | | | |
| (a) Short-Term Borrowings | | - | - |
| (b) Trade Payables | | - | - |
| (c) Other Current Liabilities | 3.03 | 15.26 | 4.27 |
| (d) Short-Term Provisions | 3.04 | 0.24 | 0.24 |
| | | 123.60 | 97.06 |
| II. ASSETS | | | |
| (1) Non-Current Assets | | | |
| (a) Property, Plant and Equipment (PPE) | 3.05 | | |
| (i) Tangible Assets | | 79.91 | 90.68 |
| (ii) Intangible Assets | | 0.12 | 0.17 |
| (b) Long term Loans and Advances | | - | - |
| (c) Investment | | - | - |
| (2) Current Assets | | | |
| (a) Trade Receivables | | - | - |
| (b) Cash and Bank Balances | 3.06 | 43.66 | 5.60 |
| (c) Other Current Assets | 3.07 | (0.09) | 0.61 |
| | | 123.60 | 97.06 |
| As per our report attached | | For and on behalf of Directors of MOC Cancer Care foundation | |
| For P. L. Raval & Co. Chartered Accountants FRN 0108747W  Piyush L. Raval Proprietor M No:031888 Place: Mumbai Date:- 29 SEP 2025  | |  Dr. Vashista P. Maniar (Director) DIN:07958648  Dr. Preetam Kalaskar (Director) DIN:07958660  Dr. Ashish A. Joshi (Director) DIN:07958653  Dr. Kshitij Joshi (Director) DIN:07958657 | |

UDIN: 25031888BMN2KU7528



INCOME & EXPENDITURE STATEMENT FOR PERIOD ENDED 31 MAR 2025

| MOC CANCER CARE FOUNDATION (A Company Licensed under Section 8 of the Companies Act, 2013) STATEMENT OF INCOME & EXPENDITURE FOR THE PERIOD ENDED ON 31ST MARCH, 2025 (All amounts in INR Lakhs unless otherwise stated) | | | |
|---|----------|--|---|
| Particulars | Note No. | For the Period Ended 31/03/2025 ₹ | For the Period Ended 31/03/2024 ₹ |
| INCOMES | | | |
| Income from Operation | 3.08 | 81.38 | 29.58 |
| Other Income | 3.09 | 0.00 | 0.15 |
| Total Income | | 81.38 | 29.73 |
| EXPENSES | | | |
| Employee Benefit Expenses | 3.10 | 20.32 | 8.21 |
| Depreciation and Amortization Expense | 3.05 | 1.06 | 0.20 |
| Utilization on Programmes and Activities | 3.11 | 7.08 | 34.93 |
| Other Expenses | 3.12 | 26.34 | 3.24 |
| Total Expenses | | 54.80 | 46.58 |
| Surplus / (Deficit) for the period | | 26.58 | (16.85) |
| Surplus / (Deficit) for the carried forward | | 26.58 | (16.85) |
| Tax Expense: | | | |
| (a) Current Tax | | 0.45 | - |
| (b) Tax of earlier years w/off | | 0.44 | - |
| Surplus / (Deficit) for the carried forward | | 25.70 | 16.85 |
| As per our report attached | | For and on behalf of Directors of MOC Cancer Care foundation | |
| For P. L. Raval & Co. Chartered Accountants FRN 0108747W  Piyush L. Raval Proprietor M No:031888 Place: Mumbai Date:- 29 SEP 2025 | |  Dr. Vashista P. Maniar (Director) DIN:07958648 | |
|  | |  Dr. Preetam Kalaskar (Director) DIN:07958660 | |
| | |  Dr. Kshish A. Joshi (Director) DIN:07958653 | |
| | |  Dr. Kshitij Joshi (Director) DIN:07958657 | |

UDIN: 25031888BMNocKu7528



ACKNOWLEDGEMENT

The MOC Cancer Care Foundation conveys its deep appreciation to all individuals and institutions who have stood by us during the year **2024–25**.

This year represents a phase of accelerated outreach and strengthened on-ground presence. The introduction of our dedicated mobile screening van, coupled with the relentless efforts of our field team, enabled us to significantly increase the number of screening camps conducted. This enhanced mobility has allowed us to access remote and underserved communities more efficiently, ensuring wider reach and continuity of care.

We extend our sincere thanks to our supporters and contributors—including **Tata Capital Financial Services Ltd, VUB Foundation, SBI General Insurance Company Limited, Novartis Healthcare Pvt Ltd, and Cellcure Cancer Centre Pvt Ltd – Pharma**—whose encouragement and generosity have been instrumental in making this progress possible. Your belief in our mission continues to drive our efforts toward creating meaningful and measurable impact.

We are equally grateful to our collaborating institutions, healthcare experts, and advisors for their continued association and valuable guidance. Their support reinforces the quality and credibility of our initiatives.

Our appreciation also goes to the volunteers and community-based workers whose dedication and consistent engagement at the grassroots level have been vital to our success. Lastly, we acknowledge the commitment of our team members, whose sustained efforts and sense of purpose have enabled the organization to grow and reach new milestones.

We look forward to building on this momentum with your continued support in the years ahead.

MOC CANCER CARE FOUNDATION



CANCER CARE FOUNDATION

CONTACT US

REGISTERED OFFICE: 1st & 2nd Floor, Shree Saraswati Apartments, CHSL, Opp. Bhagwati Hospital, S.V. Road, Borivali West, Mumbai – 400092

COMMUNICATION & NETWORKING ADDRESS: 3RD, 4TH & 5TH Floor, Time Square Building, Scindia Society, Bima Nagar, Andheri East, Mumbai, Maharashtra 400069

WEBSITE: www.mocfoundation.com

WRITE TO US: msw@mocfoundation.com

CONTACT US: +91 86574 90578

LinkedIn: MOC Cancer Care Foundation

Instagram: www.instagram.com/mocfoundation2022/

Facebook: www.facebook.com/p/MOC-Cancer-Care-Foundation-100082982348764/

